Journal: Biochemistry and Biophysics Reports

Article Title: The TAAR1 antagonist EPPTB ameliorates colitis via serotonin inhibition

doi: 10.1016/j.bbrep.2025.102432

Figure Lengend Snippet: Fecal Tryp, PEA, and Tyr in UC and DSS-colitis mice, and TAAR1 inhibition attenuates their 5-HT release from QGP-1 cells and mouse ex vivo colonic tissues. (A) Fecal levels of Tryp, PEA, and Tyr in healthy control (n = 15) and UC patients (n = 20). (B) Fecal levels of Tryp, PEA, and Tyr in Control (Con) mice and DSS-induced colitis mice (n = 12). Student's t-test were used to determine differences between two groups in Data A and B. (C) The 5-HT levels in QGP-1 cells following 24-h treatments with PEA, Tryp, or Tyr (20 μM) alone, and each amine in combination with EPPTB (20 μM) (n = 3). (D) The 5-HT levels in mouse ex vivo colonic tissues following 2-h treatments with PEA, Tryp, or Tyr (50 μM) alone, or each amine in combination with EPPTB (50 μM) (n = 4). One-way ANOVA followed by Tukey's multiple comparisons test was used to determine differences between two groups in Data C and D. Data are presented as means ± SD. * P < 0.05, ** P < 0.01, ***P < 0.001 and **** P < 0.0001.

Article Snippet: Following one cycle of DSS administration, all mice developed consistent colitis and were randomly allocated into two groups (n = 6 per group): DSS alone, and DSS plus EPPTB (10 mg/kg; MedChemExpress, New Jersey, USA).

Techniques: Inhibition, Ex Vivo, Control